Association of Complement C3 with Clinical Deterioration Among Hospitalized Patients with COVID-19

References

• Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324. doi:10.1001/jama.2020.12839.
   Web of Science ®Google Scholar
• Nesargikar PN, Spiller B, Chavez R. The complement system: history, pathways, cascade and inhibitors. Eur J Microbiol Immunol. 2012;2:103–111. doi:10.1556/EuJMI.2.2012.2.2
   Google Scholar
• Jiang Y, Zhao G, Song N, et al. Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018;7(1):77. doi:10.1038/s41426-018-0063-8
   PubMed Web of Science ®Google Scholar
• Jiang Y, Li J, Teng Y, et al. Complement receptor C5aR1 inhibition reduces pyroptosis in hDPP4-transgenic mice infected with MERS-CoV. Viruses. 2019;11(1):39. doi:10.3390/v11010039
   PubMed Web of Science ®Google Scholar
• Gralinski LE, Sheahan TP, Morrison TE, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio. 2018;9(5):e01753–18. doi:10.1128/mBio.01753-18
   PubMed Web of Science ®Google Scholar
• Polycarpou A, Howard M, Farrar CA, et al. Rationale for targeting complement in COVID-19. EMBO Mol Med. 2020;12(8):e12642. doi:10.15252/emmm.202012642
   PubMed Web of Science ®Google Scholar
• Skendros P, Mitsios A, Chrysanthopoulou A, et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest. 2020;130(11):6151–6157. doi:10.1172/JCI141374
   PubMed Web of Science ®Google Scholar
• Fang S, Wang H, Lu L, Jia Y, Xia Z. Decreased complement C3 levels are associated with poor prognosis in patients with COVID-19: a retrospective cohort study. Int Immunopharmacol. 2020;89(Pt A):107070. doi:10.1016/j.intimp.2020.107070
   PubMed Web of Science ®Google Scholar
• Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762–768. doi:10.1093/cid/ciaa248
   PubMed Web of Science ®Google Scholar
• Zhang Z, Li X, Zhang W, Shi ZL, Zheng Z, Wang T. Clinical features and treatment of 2019-nCov pneumonia patients in Wuhan: report of a couple cases. Virol Sin. 2020;35(3):330–336. doi:10.1007/s12250-020-00203-8
   PubMed Web of Science ®Google Scholar
• China NHC. Guidelines of the diagnosis and treatment of novel coronavirus pneumonia (trial version 8). in Chinese. Available from: http://www.nhc.gov.cn/yzygj/s7653p/202008/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a.shtml. Accessed January 15, 2022
   Google Scholar
• Birmingham DJ, Irshaid F, Nagaraja HN, et al. The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus. 2010;19(11):1272–1280. doi:10.1177/0961203310371154
   PubMed Web of Science ®Google Scholar
• Complement component 3 (C3) [website on the Internet]. UCSF Benioff Children's Hospitals; 2022. Available from: https://www.ucsfbenioffchildrens.org/medical-tests/003539. Accessed January 15, 2022.
   Google Scholar
• How to Read Complement C3 Test Report [website on the Internet]. MediFee.com; 2022. Available from: https://www.medifee.com/how-to-read/complement-c3-test-report. Accessed January 15, 2022.
   Google Scholar
• C3 And C4 Blood Test [website on the Internet]. PORTEA – HEAL AT HOME; 2022. Available from: https://www.portea.com/labs/diagnostic-tests/c3-and-c4-blood-test-204/. Accessed January 15, 2022.
   Google Scholar
• Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med. 2020;382(24):2327–2336. doi:10.1056/NEJMoa2007016
   PubMed Web of Science ®Google Scholar
• Stuart EA, Lee BK, Leacy FP. Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. J Clin Epidemiol. 2013;66(8 Suppl):S84–S90.e1. doi:10.1016/j.jclinepi.2013.01.013
   PubMed Web of Science ®Google Scholar
• West EE, Kolev M, Kemper C. Complement and the regulation of T cell responses. Annu Rev Immunol. 2018;36:309–338. doi:10.1146/annurev-immunol-042617-053245
   PubMed Web of Science ®Google Scholar
• Nasir A, Caetano-Anolles G. A phylogenomic data-driven exploration of viral origins and evolution. Sci Adv. 2015;1(8):e1500527. doi:10.1126/sciadv.1500527
   PubMed Web of Science ®Google Scholar
• Janssen BJ, Huizinga EG, Raaijmakers HC, et al. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature. 2005;437(7058):505–511. doi:10.1038/nature04005
   PubMed Web of Science ®Google Scholar
• Ricklin D, Reis ES, Mastellos DC, Gros P, Lambris JD. Complement component C3 – the ”Swiss Army Knife” of innate immunity and host defense. Immunol Rev. 2016;274(1):33–58. doi:10.1111/imr.12500
   PubMed Web of Science ®Google Scholar
• Atsumi T, Amengual O, Koike T. Antiphospholipid syndrome: pathogenesis. In: Systemic Lupus Erythematosus. Fifth ed. Academic Press; 2011:945–965.
   Google Scholar
• Lin RY, Astiz ME, Saxon JC, Saha DC, Rackow EC. Alterations in C3, C4, factor B, and related metabolites in septic shock. Clin Immunol Immunopathol. 1993;69(2):136–142. doi:10.1006/clin.1993.1161
   PubMedGoogle Scholar
• Hashizume H, Kageyama R. Hypocomplementemia is a diagnostic clue for parvovirus B19 infection in adults. J Dermatol. 2017;44(3):e27. doi:10.1111/1346-8138.13469
   PubMed Web of Science ®Google Scholar
• Brudner M, Karpel M, Lear C, et al. Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors. PLoS One. 2013;8:e60838. doi:10.1371/journal.pone.0060838
   PubMed Web of Science ®Google Scholar
• Itoh K, Tanaka H, Shiga J, et al. Hypocomplementemia associated with hepatitis C viremia in sera from voluntary blood donors. Am J Gastroenterol. 1994;89(11):2019–2024.
   PubMed Web of Science ®Google Scholar
• Licciardi F, Pruccoli G, Denina M, et al. SARS-CoV-2-induced Kawasaki-like hyperinflammatory syndrome: a novel COVID phenotype in children. Pediatrics. 2020;146(2):e20201711. doi:10.1542/peds.2020-1711
   PubMed Web of Science ®Google Scholar
• Regev T, Antebi M, Eytan D, et al. Pediatric inflammatory multisystem syndrome with central nervous system involvement and hypocomplementemia following SARS-COV-2 infection. Pediatr Infect Dis J. 2020;39(8):e206–e207. doi:10.1097/INF.0000000000002804
   PubMed Web of Science ®Google Scholar
• Engström G, Hedblad B, Berglund G, Janzon L, Lindgärde F. Plasma levels of complement C3 is associated with development of hypertension: a longitudinal cohort study. J Hum Hypertens. 2007;21(4):276–282. doi:10.1038/sj.jhh.1002129
   PubMed Web of Science ®Google Scholar
• Engström G, Hedblad B, Eriksson KF, Janzon L, Lindgärde F. Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes. 2005;54(2):570–575. doi:10.2337/diabetes.54.2.570
   PubMed Web of Science ®Google Scholar
• Engström G, Hedblad B, Janzon L, Lindgärde F. Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study. Eur J Cardiovasc PrevRehabil. 2007;14(3):392–397. doi:10.1097/01.hjr.0000244582.30421.b2
   PubMedGoogle Scholar
• Risitano AM, Mastellos DC, Huber-Lang M, et al. Complement as a target in COVID-19? Nat Rev Immunol. 2020;20(6):343–344. doi:10.1038/s41577-020-0320-7
   PubMed Web of Science ®Google Scholar
• Gao T, Hu MD, Zhang XP, Li HZ, Cao C. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. medRxiv. 2020. doi:10.1101/2020.03.29.20041962
   Google Scholar
• Mastellos DC, Yancopoulou D, Kokkinos P, et al. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur J Clin Invest. 2015;45(4):423–440. doi:10.1111/eci.12419
   PubMed Web of Science ®Google Scholar
• Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov. 2018;18:707–729. doi:10.1038/s41573-019-0031-6
   Web of Science ®Google Scholar
• Mastaglio S, Ruggeri A, Risitano AM, et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020;215:108450. doi:10.1016/j.clim.2020.108450
   PubMed Web of Science ®Google Scholar
• Mastellos DC, Pires da Silva BGP, Fonseca BAL, et al. Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy. Clin Immunol. 2020;220:108598. doi:10.1016/j.clim.2020.108598
   PubMed Web of Science ®Google Scholar